Taliglucerase alfa

Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA

Retrieved on: 
Monday, August 2, 2021
Life sciences, Protalix BioTherapeutics, Biotechnology, Companies, Taliglucerase alfa, Biopharmaceutical, Food and Drug Administration, Pharming

The Type A Meeting is expected to occur within 30 days of the FDA's receipt of the meeting request.

Key Points: 
  • The Type A Meeting is expected to occur within 30 days of the FDA's receipt of the meeting request.
  • Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx.
  • Protalix was the first company to gain U.S.Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system.
  • Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.

Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021

Retrieved on: 
Monday, June 28, 2021
Life sciences, Protalix BioTherapeutics, Companies, Biotechnology, Taliglucerase alfa, Biopharmaceutical, Molecular biology, Pharming

A replay will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

Key Points: 
  • A replay will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.
  • Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx.
  • Protalix was the first company to gain U.S.Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system.
  • Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.

Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021

Retrieved on: 
Friday, May 7, 2021
Life sciences, Biotechnology, Biology, Protalix BioTherapeutics, PLX, Taliglucerase alfa, Recombinant DNA, Chiesi Farmaceutici, Protein production, Biopharmaceutical

b"CARMIEL, Israel, May7, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today announced that it will release its financial results for the first quarter 2021 and business update on Friday, May14, 2021.

Key Points: 
  • b"CARMIEL, Israel, May7, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today announced that it will release its financial results for the first quarter 2021 and business update on Friday, May14, 2021.
  • Protalix was the first company to gain U.S.Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system.
  • Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.\nProtalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries.
  • Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa, and with SarcoMed USA, Inc. for the worldwide development and commercialization of PRX110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery.\n"

Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021

Retrieved on: 
Monday, March 22, 2021
Companies, Protalix BioTherapeutics, Taliglucerase alfa, Pfizer

The Company's management will host a conference call to discuss the financial results and provide abusiness update on recent corporate and clinical developments at 8:30 a.m. Eastern Daylight Time (EDT).

Key Points: 
  • The Company's management will host a conference call to discuss the financial results and provide abusiness update on recent corporate and clinical developments at 8:30 a.m. Eastern Daylight Time (EDT).
  • The conference call will be available for replay for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.
  • Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx.
  • Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.

Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Thursday, March 4, 2021
Life sciences, Protalix BioTherapeutics, Companies, Health sciences, Pharmaceutical industry, Biotechnology, Taliglucerase alfa, Biopharmaceutical, Pfizer, Medication, Molecular biology, Pharming

Those interested in registering for the conference can do so here: https://hcwevents.com/globalconference/ .

Key Points: 
  • Those interested in registering for the conference can do so here: https://hcwevents.com/globalconference/ .
  • Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx.
  • Protalix was the first company to gain U.S.Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system.
  • Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.

Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021

Retrieved on: 
Wednesday, February 10, 2021
Companies, Protalix BioTherapeutics, Taliglucerase alfa, Alpha-galactosidase, Rare disease, Pfizer, Chiesi Farmaceutici

"The final analysis of the BRIDGE Study in Fabry patients previously treated with agalsidase alfa demonstrates a potential benefit of pegunigalsidase alfa on renal function," said Prof. Linhart.

Key Points: 
  • "The final analysis of the BRIDGE Study in Fabry patients previously treated with agalsidase alfa demonstrates a potential benefit of pegunigalsidase alfa on renal function," said Prof. Linhart.
  • Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders.
  • Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
  • Protalix has partnered with Chiesi Global Rare Diseases, both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021

Retrieved on: 
Monday, February 1, 2021
Life sciences, Protalix BioTherapeutics, Companies, Biotechnology, Taliglucerase alfa, Biopharmaceutical, Pfizer, Molecular biology, Pharming

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx.

Key Points: 
  • Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx.
  • Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system.
  • Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
  • Protalix has partnered with Chiesi Global Rare Diseases, both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January

Retrieved on: 
Monday, January 4, 2021
Protalix BioTherapeutics, Life sciences, Companies, Biotechnology, Taliglucerase alfa, Biopharmaceutical, Molecular biology

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx.

Key Points: 
  • Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx.
  • Protalix was the first company to gain FDAapproval of a protein produced through plant cell-based in suspension expression system.
  • Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
  • Protalix has partnered with Chiesi Global Rare Diseases,both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30

Retrieved on: 
Thursday, October 29, 2020
Companies, Protalix BioTherapeutics, Taliglucerase alfa, Pfizer, Food and Drug Administration, Health care

The rescheduled call to discuss the financial results and provide a general business update will take place on Friday, October30, 2020at 8:30a.m.

Key Points: 
  • The rescheduled call to discuss the financial results and provide a general business update will take place on Friday, October30, 2020at 8:30a.m.
  • Eastern Daylight Time (EDT).The Company reported financial results for the third quarter ended September30, 2020, and provided a business update on recent corporate and clinical developments in a press release issued earlier today.
  • The conference call will be available for replay for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.
  • Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA inMay 2012and, subsequently, by the regulatory authorities of other countries.Protalixhas licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excludingBrazil, whereProtalixretains full rights.

Protalix BioTherapeutics to Participate in Virtual Investor KOL Roundtable

Retrieved on: 
Monday, October 26, 2020
Companies, Protalix BioTherapeutics, Taliglucerase alfa, Pfizer

The KOL Roundtable is taking place virtually on Tuesday, October27 through Thursday, October29.

Key Points: 
  • The KOL Roundtable is taking place virtually on Tuesday, October27 through Thursday, October29.
  • The Company's Roundtable presentation will be a live video webcast, moderated discussion for up to one hour.
  • received a BA degree in 1966 from the University of California at Berkeley and received his M.D.
  • Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.